Tuesday, February 27, 2024
Elsie Bio is focused on applying medicinal chemistry to oligonucleotide development. We use DNA encoded technology to design and develop optimal RNA therapeutics. Our approach is redefining how we treat diseases, offering targeted solutions with unprecedented activity and accuracy. With a commitment to groundbreaking science, we're leading the way in developing next-generation RNA therapeutics. Capitalizing on partnerships and data, we intend to develop an unparalleled neurodegenerative pipeline addressing major unmet needs. Our company uses DNA-encoded ultra-high throughput screening to discover optimal sequences and chemical architectures in order to develop therapies with better drug properties. We apply novel chemistry to these optimized molecules that allows access to novel backbones and structures to improve delivery and safety of therapeutics. Our lead assets are in CNS with a focus on treating neurodegenerative diseases in a non-invasive, cell-specific manner.
CEO/Top Company Official
Lead Product in Development
antisense treating Parkinson's disease
Development Phase of Primary Product